Checks thinking and memory after chemotherapy in young adults with Hodgkin disease
Studies memory, thinking and brain scans in young adults with Hodgkin disease after chemotherapy.
Plain-language title generated from the registry record
Registry title: Hodgkin's Disease and Chemotherapy Before 40 Years
Key facts
- Where
- Arras, Lille, Lomme, and Roubaix, FranceSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT06116929, who can take part
Where in France
- Centre Hospitalier Artois TernoisArras, FranceNo longer taking part
- Hopital Claude HuriezLille, FranceNo longer taking part
- Hopital Saint PhilibertLomme, FranceNo longer taking part
- Hopital Victor ProvoRoubaix, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lille Catholic University
- Trial code
- NCT06116929
- Record updated
- 28 February 2024
- Original description
A few studies have focused on other solid cancers (colorectal, prostate). On the other hand, the study of cognitive impairment in Hodgkin's disease remains less developed, and structural and functional post-therapy MRI studies have never been carried out. The impact of cognitive impairment on Hodgkin's disease is rarely, if ever, assessed in routine clinical practice, despite the fact that it is truly disabling in 16 to 30% of patients. Cognitive impairment can persist long after diagnosis and treatment. A recent study examining cognitive functioning in patients an average of 13 years after treatment found that disorders persisted in 52% of cases, with attentional, working memory and dysexecutive (planning) difficulties. These disorders have a significant impact on the daily and professional lives of these young, often working patients. Their rapid development and persistence after treatment can therefore represent a real limiting factor, impacting both professional integration and quality of life. Finally, the current state of knowledge does not allow us to dissociate cognitive disorders from emotional disorders and fatigue, which represent a major patient complaint. A better definition of the nature, pathophysiology and specificity of these disorders would therefore enable us to take better account of their repercussions (social, professional and on quality of life) and provide better care (in terms of cognitive remediation or psychological support).Read full original descriptionShow less
Functional and Cognitive Assessment of Patients With Hodgkin's Disease Undergoing Chemotherapy Before 40 Years
A few studies have focused on other solid cancers (colorectal, prostate). On the other hand, the study of cognitive impairment in Hodgkin's disease remains less developed, and structural and functional post-therapy MRI studies have never been carried out. The impact of cognitive impairment on Hodgkin's disease is rarely, if ever, assessed in routine clinical practice, despite the fact that it is truly disabling in 16 to 30% of patients. Cognitive impairment can persist long after diagnosis and treatment. A recent study examining cognitive functioning in patients an average of 13 years after treatment found that disorders persisted in 52% of cases, with attentional, working memory and dysexecutive (planning) difficulties. These disorders have a significant impact on the daily and professional lives of these young, often working patients. Their rapid development and persistence after treatment can therefore represent a real limiting factor, impacting both professional integration and quality of life. Finally, the current state of knowledge does not allow us to dissociate cognitive disorders from emotional disorders and fatigue, which represent a major patient complaint. A better definition of the nature, pathophysiology and specificity of these disorders would therefore enable us to take better account of their repercussions (social, professional and on quality of life) and provide better care (in terms of cognitive remediation or psychological support).
A prospective, longitudinal, multicenter, case-control interventional study in which cases are patients with Hodgkin's disease (HD) treated with CT +/- radiotherapy and controls are healthy participants will be conducted. The aim is to study the prevalence and nature of treatment-induced cognitive impairment and its correlation with emotional comorbidities, as well as structural and functional brain disorders on MRI. The patient will thus be his or her own witness, the reference state being that at the time of diagnosis, before any treatment. The fact that this state has not already been altered by the disease itself, will be verify thanks to comparison with controls.
Inclusion: Patient with newly diagnosed Hodgkin's disease; With intention to treat with chemotherapy +/- radiotherapy; Aged between 18 and 40 years; Fluency in French; Able to undergo neuropsychological evaluation (absence of major sensory disorders); Agreeing to take part in the study and having signed the informed consent form; Affiliated with a social security scheme; Individual without Hodgkin's disease; Aged between 18 and 40; Proficient in French; Agreeing to participate in the study and having signed the informed consent form; Affiliated with a social security scheme; Cases and controls will be matched on age (± 5 years difference), and number of years of education (difference ≤ 2 years); Non-inclusion criteria - cases + controls :; Claustrophobia preventing MRI from being performed; Contraindication to MRI; Previous chemotherapy; History of neurological or psychiatric illness, including severe depression, or cognitive impairment; Use of medications that may cause neurological or psychiatric signs; Alcohol or drug abuse; Pregnant women; Persons under guardianship or trusteeship.